Management of COVID-19 and Preparing clinic for upcoming winter and expectation of infectivity rate

Management of COVID-19 and Preparing clinic for upcoming winter and expectation of infectivity rate

Coronavirus

90 Mins

English Site

Recoded Webinar

Online

Course Overview

 

Indian Medical Association East Delhi cordially invites you all to interactive recorded live webinar session on topic "Management of COVID-19 and Preparing clinic for upcoming winter and expectation of infectivity rate ".

HIGHLIGHTS OF THE WEBINAR 
 
Module 1 - Treatment options for COVID-19 mild to moderate (use of Favipiravir) & preparing clinic 
for upcoming winter and expectation of infectivity rate: Dr Dhiren Gupta 

AIM of treatment 
●Standard way of treatment of mild to moderate cases  
●Use of Favipiravir  
●Practical tip- case based approach  
●Case 1 - stratifying the case 
●Treatment (mild / moderate/ severe)  
●Follow-up instructions – clinical targets, red flag and investigations  
●Spectrum of COVID-19 
●Pathogenesis of the virus – Phases with respect to onset of the symptoms  
●In patient vital status of the patient with charts explained  
●Case 2 – Day wise status of patient with treatment given  
●Further cases were discussed management day wise symptoms, status and management  

Lessons learnt  
●Faviparavir may not have role in high risk patients  
●Better than ivermectin  
●Radiological interpretation in important  

Role of radiology  
●Pulmonary phase 
●Corelation with score and severity  
●NIH Guidelines and treatment (mild, moderate and severe disease definitions) 

Favipiravir  
●What is Favipiravir and dosage  
●Side effects  
●Drug interactions  
●Trails supporting Favipiravir  
 
Conclusion  

●When to use early antivirals (Favipiravir/Remdesivir) 
●When to Shift from Favipiravir to Remdisivir (based radiology and symptoms) 
●Management of patient explained with respect to risk, symptoms and radiological staging   
●Winters will increase the severity and transmission  
 
Module 2 - Treatment options for COVID-19 moderate to severe (Use of Remdesivir in reducing 
Mortality rate): Dr Atul Gogia 

●Classification of severity COVID-19 
●Key therapeutic classes under evaluation for treatment of COVID-19 (antiviral 
and immunomodulator)  
●Therapies predicted to provide benefits at different stages in COVID-19 

Remdesivir  
●Treatment initiation and dosing regimens  
●Safety information and warnings for Remdisivir  
●Remdisivir Trail 
●NIAID ACTT1 – Clinical Status Ordinal Scale  
●Efficacy and safety of Remdisivir 
●Simple severe study trail explained  
●Simple moderate study explained  
●Various studies on Remdesivir described 
 
Dexamethasone 

●Composition and dosing  
●Trails on dexamethasone discussed  
●Trail on hydrocortisone use in COVID-19  
●NIH/ISDA – Recommendations and guideline to use dexamethasone and other corticosteroids 

Plasma therapy  
●Passive immunity  
●Use of Monoclonal Antibodies, Hyperimmune Immunoglobulins and Convalescent Plasma  
●Trails regarding use of Plama therapy discussed  

Conclusion  
●Remdesivir  
●Steroids  
●Appropriate patient selection and timing is the key 
  
Module 3 – Question and Answer session  

The questions of delegates were discussed in a very interactive and informative session . 
 
We wish you a great learning experience and thank Indian Medical Association East Delhi for hosting this session. We also thank our sponsors Mylan Pharmaceuticals Pvt. Ltd. to make this program possible.


Trainers



Free
Coming session Starts Oct 23, 2020
Ends Jan 23, 2021